Multiple Sclerosis Drugs - Mauritius

Mauritius

The Multiple Sclerosis Drugs market in Mauritius is anticipated to achieve a projected revenue of US$1.50m in 2024.
This revenue is expected to exhibit an annual growth rate (CAGR 2024-2029) of 2.17%, leading to a market volume of US$1.67m by 2029.
When compared globally, United States is projected to generate the highest revenue in this market, amounting to US$11,770.00m in 2024.
The demand for Multiple Sclerosis Drugs in Mauritius is on the rise due to an increasing number of diagnosed cases.

Key regions: France, India, United Kingdom, South Korea, Japan

Market

Region

Region comparison

Currency

Analyst Opinion

The Multiple Sclerosis Drugs market in Mauritius has been developing steadily in recent years.

Customer preferences: Patients in Mauritius suffering from Multiple Sclerosis (MS) tend to prefer drugs that are effective in reducing the frequency and severity of relapses, as well as those that have minimal side effects. They also prefer drugs that are affordable and easily accessible.

Trends in the market: The Multiple Sclerosis Drugs market in Mauritius has been growing due to the increasing prevalence of MS in the country. This has led to an increase in demand for drugs that can help manage the symptoms of the disease. In addition, there has been a shift towards the use of newer drugs that are more effective in reducing relapses and have fewer side effects. However, the high cost of these drugs remains a challenge for many patients.

Local special circumstances: Mauritius has a small population, which limits the size of the market for Multiple Sclerosis Drugs. As a result, drug companies may be less motivated to invest in the development of new drugs specifically for the Mauritian market. In addition, the country has a public healthcare system that provides free or subsidized healthcare to its citizens, which may limit the growth of the private healthcare sector.

Underlying macroeconomic factors: Mauritius has a relatively stable economy with a growing middle class. This has led to an increase in demand for healthcare services, including drugs for the treatment of chronic diseases such as MS. However, the high cost of MS drugs may limit access to these drugs for many patients, particularly those who cannot afford private healthcare. In addition, the country's reliance on imports for many goods, including pharmaceuticals, makes it vulnerable to fluctuations in global markets.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.